Moderna Net Income

MRNA
 Stock
  

USD 149.95  7.10  4.97%   

Moderna fundamentals help investors to digest information that contributes to Moderna's financial success or failures. It also enables traders to predict the movement of Moderna Stock. The fundamental analysis module provides a way to measure Moderna's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Moderna stock. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  
Refresh
The current year Net Income is expected to grow to about 13.2 B. The current year Net Income Common Stock is expected to grow to about 13.2 B.

Moderna Net Income Analysis

Moderna's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Moderna Net Income

13.17 Billion

Share
Net Income 
 = 
(Rev + Gain) 
-  
(Exp + Loss) 
More About Net Income | All Equity Analysis

Current Moderna Net Income

    
  12.2 B  
Most of Moderna's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Moderna is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Moderna Net Income Driver Correlations

Understanding the fundamental principles of building solid financial models for Moderna is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Net Income. Since Moderna's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Moderna's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Moderna's interrelated accounts and indicators.

Moderna Net Income Historical Pattern

Today, most investors in Moderna Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Moderna's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's net income growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Moderna net income as a starting point in their analysis.
 Moderna Net Income 
Share
      Timeline 
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Compare to competition

Moderna Accumulated Other Comprehensive Income

Accumulated Other Comprehensive Income

(24.63 Million)

Share
Moderna Accumulated Other Comprehensive Income is projected to decrease significantly based on the last few years of reporting. The past year's Accumulated Other Comprehensive Income was at (24 Million)
Based on the recorded statements, Moderna reported net income of 12.2 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Biotechnology industry. The net income for all United States stocks is significantly lower than that of the firm.

Moderna Current Valuation Drivers

We derive many important indicators used in calculating different scores of Moderna from analyzing Moderna's financial statements. These drivers represent accounts that assess Moderna's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Moderna's important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(235.46 M)(359.55 M)(484 M)(651 M)13.52 B14.58 B
Earnings Before Interest Taxes and Depreciation Amortization USD(235.46 M)(359.55 M)(484 M)(651 M)13.52 B14.58 B
Earnings before Tax(256 M)(384.41 M)(515 M)(744 M)13.29 B14.33 B
Free Cash Flow(389.88 M)(436.63 M)(491 M)1.96 B13.34 B14.39 B
Invested Capital772.9 M1.11 B1.34 B531 M9.4 B10.14 B
Tangible Asset Value1.08 B1.96 B1.59 B7.34 B24.67 B26.62 B
Working Capital591.76 M1.34 B985.69 M1.91 B6.94 B7.49 B

Moderna Institutional Holders

Institutional Holdings refers to the ownership stake in Moderna that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Moderna's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Moderna's value.
Security TypeSharesValue
Baillie Gifford CoCommon Shares45.6 M7.9 B
Blackrock IncCommon Shares28.7 M4.9 B
Vanguard Group IncCommon Shares27 M4.7 B
Flagship Pioneering IncCommon Shares17.6 MB
State Street CorpCommon Shares14.8 M2.6 B
Coatue Management LlcCommon Shares6.9 M1.2 B
Geode Capital Management LlcCommon Shares6.4 M1.1 B
Susquehanna International Group LlpCall Options4.2 M716.5 M
Susquehanna International Group LlpPut Options3.9 M669.8 M

Moderna Fundamentals

About Moderna Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Moderna's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Moderna using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Moderna based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2022
Net Income12.2 B13.2 B
Net Income Common Stock12.2 B13.2 B
Net Income Per Employee4.5 M4.9 M
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States and internationally. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. Moderna operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 2700 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Moderna without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Bond Directory Now

   

Bond Directory

Find actively traded corporate debentures issued by US companies
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Moderna using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Moderna Piotroski F Score and Moderna Altman Z Score analysis. Note that the Moderna information on this page should be used as a complementary analysis to other Moderna's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Complementary Tools for Moderna Stock analysis

When running Moderna price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Is Moderna's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
2.02
Market Capitalization
59.6 B
Quarterly Revenue Growth YOY
2.13
Return On Assets
0.5
Return On Equity
1.4
The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine Moderna value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.